Direct answer: As of September 2026, the talcum powder litigation remains active in the United States. Johnson & Johnson has proposed a $5.5 billion resolution covering roughly 76,000 ovarian-cancer claims, subject to participation requirements, while 69,250 actions were pending in federal MDL 2738 as of September 1.
A talcum powder lawsuit claims that long-term talc use may contribute to cancer. The most common claims involve ovarian cancer and mesothelioma. Johnson & Johnson has faced tens of thousands of these claims. The company denies that its talc products caused cancer or contained asbestos. The litigation has involved federal MDL proceedings, state courts, bankruptcy attempts, and individual trials. It has now moved toward a major proposed settlement program.
The $5.5 billion arrangement announced in July 2026 mainly covers ovarian cancer claims. Mesothelioma claims follow a different path. Legal deadlines also vary by state and individual circumstances. This guide explains what has happened, what the science shows, and who may have a claim. It also explains what current claimants should know before relying on advertised payout estimates.
Key Takeaways
- Johnson & Johnson announced a proposed $5.5 billion resolution on July 27, 2026. It covers about 76,000 remaining ovarian talc claims. The deal requires at least 95% participation from claimants.
- The U.S. Judicial Panel on Multidistrict Litigation reported 69,250 pending actions in MDL 2738 as of September 1, 2026.
- The Talc Claims Resolution Program is contacting claimants through participating law firms.
- The current ovarian-cancer resolution should remain separate from mesothelioma claims, which have largely followed a different legal path.
- There is no reliable universal “average payout” that can predict what an individual claimant will receive.
- Medical and scientific authorities do not describe the evidence in identical terms, making it important to distinguish an association found in studies from proof that talc caused a particular person’s cancer.
What Is the Talcum Powder Lawsuit About?
Talc is a naturally occurring mineral used for decades in products such as body powders and cosmetics because it absorbs moisture and reduces friction. Talc deposits can occur near asbestos in the earth, which has raised concerns about possible contamination during mining and production. Asbestos itself is a known human carcinogen, while questions surrounding asbestos-free talc and ovarian cancer have produced a more complicated scientific record.
Plaintiffs in the litigation generally allege that use of talc-based products exposed them to a cancer risk and that manufacturers failed to give adequate warnings. The federal proceedings initially included allegations involving Johnson’s Baby Powder and Shower to Shower, including claims concerning perineal use and ovarian cancer. Mesothelioma plaintiffs have also alleged exposure to asbestos associated with talc products.
Johnson & Johnson disputes those allegations and continues to maintain that its talc products were safe and did not cause cancer. The company stopped selling talc-based Johnson’s Baby Powder in the United States and Canada in 2020 and later discontinued the talc formulation globally in 2023 as it transitioned the product to cornstarch. Discontinuing a product, however, is not itself a legal admission that past products caused an individual claimant’s illness.
Talcum Powder Lawsuit Update for September 2026
The federal court formally calls the litigation In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2738. The litigation is taking place in the U.S. District Court for the District of New Jersey, with U.S. District Judge Michael A. Shipp listed as the presiding district judge. The Judicial Panel on Multidistrict Litigation’s September 1 pending-MDL report listed 69,250 pending actions and 71,935 historical actions in the MDL.
| Current development | September 2026 status |
| Federal proceeding | MDL 2738, District of New Jersey |
| Pending federal actions | 69,250 as of September 1, 2026 |
| Historical federal actions | 71,935 |
| Ovarian-cancer resolution announced | July 27, 2026 |
| J&J commitment | $5.5 billion |
| Approximate claims involved | 76,000 |
| Participation condition | At least 95% of remaining claims |
| First J&J payment | Up to $3 billion in 2027 under announced terms |
| Mesothelioma claims | Largely separate from the ovarian-cancer resolution |
The July agreement followed an important dispute over proof of specific causation in the federal proceedings. J&J stated that plaintiffs withdrew specific-causation experts in two bellwether cases, after which the court ordered plaintiffs to explain why remaining claims should not be dismissed for inability to prove that talc caused an individual claimant’s ovarian cancer. Five days later, J&J announced the $5.5 billion proposed resolution negotiated with firms leading federal and related state litigation.
The arrangement should not be described as a guaranteed $5.5 billion payout that every talc user automatically shares. Its announced terms require participation representing at least 95% of remaining ovarian claims, and compensation is being handled through a claims-resolution process rather than an equal division of one fund. Current reporting and the settlement program itself therefore provide much stronger guidance than simply dividing $5.5 billion by the number of lawsuits.
What Is the Talc Claims Resolution Program?
A dedicated Talc Claims Resolution Program, or TCRP, is now providing information to people whose law firms have identified them as eligible to participate. According to the program’s official claimant website, eligible claimants receive an Opt-In & Release by electronic delivery or mail, depending on their firm’s election. The website directs claimants to contact their own law firm for questions about eligibility, possible payment amounts, or timing.
The program also warns that an individual Opt-In & Release generally must be returned within 30 days from the date it was sent. That is a personalized program deadline and should not be confused with a state’s statute of limitations for filing a lawsuit in the first place. Anyone who has received settlement paperwork should therefore use the exact deadline stated in that communication rather than relying on a generic date found online.
Receiving program documents can also create decisions involving releases and legal rights. Signing a release typically has consequences for the underlying claim, so a claimant should understand the terms provided by their own counsel before signing. The official program specifically directs questions about eligibility and settlement values back to the claimant’s law firm rather than publishing a one-size-fits-all payment figure.
Why Did Johnson & Johnson Try to Use Bankruptcy?
Before the 2026 agreement, Johnson & Johnson attempted to resolve large portions of its talc liability through subsidiaries placed into Chapter 11. Its efforts involving LTL Management and later Red River Talc became widely associated with a restructuring tactic often nicknamed the “Texas two-step” in press coverage. The third attempt ended in March 2025 when the bankruptcy court denied confirmation of the proposed Red River plan. J&J then said it would return to the tort system rather than pursue that plan further.
That history matters because many older webpages still describe proposed bankruptcy settlements of different sizes and with different voting thresholds. Those figures should not be substituted for the July 2026 settlement terms, which involve a $5.5 billion commitment and a 95% participation condition. Readers unfamiliar with Chapter 11 can see Notepare’s explanation of what bankruptcy means and how Chapter 11 works for background on why a bankruptcy-based resolution differs from ordinary civil litigation.
The litigation returning to the tort system also helps explain why the federal MDL remained active while settlement discussions developed. Multidistrict litigation coordinates common pretrial issues among many cases, but it is not automatically a class action in which every plaintiff simply receives the same result. Federal court guidance expressly distinguishes an MDL from a class action.
Is Talcum Powder Scientifically Linked to Cancer?
The scientific picture requires careful wording because major institutions evaluate different questions and evidence in different ways. In 2024, the International Agency for Research on Cancer, part of the World Health Organization, classified talc as probably carcinogenic to humans, Group 2A. IARC based that conclusion on limited evidence for ovarian cancer in humans, sufficient evidence in experimental animals, and strong mechanistic evidence, while talc containing asbestos remains covered by asbestos’s Group 1 carcinogenic classification.
A 2024 study involving 50,884 women in the NIH Sister Study also reported a persistent positive association between genital talc use and ovarian cancer, with stronger associations among frequent and long-term users. Researchers emphasized that they used quantitative bias analyses to address limitations such as exposure misclassification and recall bias. The National Institute of Environmental Health Sciences described the results as supporting a potential association rather than proving that talc caused every cancer occurring after exposure.
Other authoritative summaries remain more cautious. The National Cancer Institute’s review of ovarian-cancer prevention evidence states that results from case-control and cohort studies have been inconsistent. It concludes that the available data are inadequate to establish an association between perineal talc exposure and increased ovarian-cancer risk. The American Cancer Society notes mixed findings and says any increased individual risk, if present, is likely to be small. These differences are a major reason legal cases frequently focus on expert testimony and on whether general scientific evidence can prove specific causation for a particular claimant.
What Does the FDA Say About Talc and Asbestos?
The FDA recognizes that talc and asbestos can occur near one another geologically and that asbestos contamination is a safety concern. Its 2023 talc sampling program tested 50 talc-containing cosmetic samples using polarized light microscopy and transmission electron microscopy, and asbestos was not detected in those samples. That result does not establish that every talc product manufactured during earlier decades was asbestos-free; it reports what the FDA found in that specific sampling program.
The agency proposed standardized asbestos-testing requirements for talc-containing cosmetics in December 2024. In November 2025, however, the FDA withdrew that proposed rule after comments raised issues warranting additional assessment before final regulations were issued. The FDA’s current talc page therefore remains a useful source for regulatory updates, but readers should not mistake the withdrawal for a finding that asbestos testing is unnecessary.
This regulatory history illustrates why lawsuit claims and public-health findings need to be stated separately. A government agency’s sampling result is not a verdict in an individual product-liability case, just as a jury verdict is not a scientific consensus statement. Courts determine liability under legal standards using the evidence presented in a particular case.
Who May Qualify to File a Talcum Powder Lawsuit?
Potential lawsuit eligibility and eligibility for the current settlement program are two separate questions. A person considering a new claim generally needs an attorney to evaluate the product used, duration and manner of exposure, medical diagnosis, causation evidence, defendants involved, and the law of the state governing the claim. Current talc litigation has focused most prominently on ovarian cancer and mesothelioma, but merely using baby powder without a qualifying injury does not establish a personal-injury claim.
| Factor attorneys may investigate | Why it matters |
| Product identity | Helps establish whether a talc-containing product is involved |
| Years and frequency of use | Helps document the alleged exposure history |
| Where the powder was applied | May be relevant to the alleged exposure pathway |
| Ovarian-cancer diagnosis | Central to the major ovarian-talc litigation |
| Mesothelioma diagnosis | May support a separate asbestos-related talc claim |
| Pathology and medical records | Documents diagnosis, type, timing, and treatment |
| Purchase or household evidence | Can help connect a claimant with a particular product |
| State and residence history | May affect applicable law and filing deadlines |
| Date of diagnosis or death | Can be important when calculating limitation periods |
Eligibility for the 2026 TCRP is narrower than simply asking whether someone might have a viable talc claim. The program’s official website says claimants are contacted after being identified by their law firms as eligible, and it tells individuals with questions about eligibility to speak with those firms. A person who has never filed a claim should therefore not assume that the existence of the $5.5 billion arrangement automatically places them in the settlement program.
Families may also have questions when the person diagnosed with cancer has died. Depending on state law and the facts, wrongful-death, survival, or estate-related claims can involve different parties and deadlines from a living person’s personal-injury claim. Those questions are state-specific and should be evaluated before assuming that an older diagnosis or death is automatically too late.
What Evidence Can Help Support a Claim?
Evidence matters because an attorney must do more than show that a person once owned talcum powder. A viable product-liability case can require proof concerning exposure, diagnosis, causation, and the defendant responsible for the product, with requirements varying under applicable state law. Records assembled early can also help counsel identify factual gaps before important documents disappear.
| Evidence to preserve | Examples |
| Medical records | Pathology, oncology records, diagnostic imaging, treatment history |
| Product information | Containers, photographs, brand names, labels, receipts |
| Exposure history | Approximate years used, frequency, body area, household use |
| Witness information | Family members or others familiar with long-term use |
| Employment records | Relevant when occupational talc or asbestos exposure may matter |
| Prior asbestos exposure | Worksites, home renovation, family exposure, other products |
| Financial records | Medical expenses, lost income, caregiving or related losses |
| Legal documents | Existing complaints, settlement notices, Opt-In & Release forms |
A claimant does not need to reconstruct decades of product use perfectly before speaking to counsel. Older exposures frequently mean receipts no longer exist, so attorneys may evaluate testimony, photographs, family recollections, historical product information, and other evidence alongside medical records. What is sufficient will depend on the particular lawsuit and jurisdiction.
It is also important to disclose other possible sources of asbestos exposure rather than assuming they should be omitted. Mesothelioma cases often require detailed exposure histories because more than one product or workplace may be relevant. Complete information helps an attorney assess causation and identify all potentially responsible parties.
Is This a Class Action or a Mass Tort?
The federal talc proceeding is an MDL, not one giant class action in which every claimant has an identical injury and automatically receives the same check. Multidistrict litigation allows lawsuits involving common factual questions to be coordinated before one federal judge for matters such as discovery, expert issues, and other pretrial proceedings. Individual cases can still retain their own facts, injuries, damages, and legal issues.
That distinction also explains why “How much will everyone get?” is the wrong question. Two people may have different diagnoses, exposure histories, ages, medical costs, causation evidence, jurisdictions, and settlement classifications. A collective settlement can use common procedures without making every underlying claim equally valuable.
The proposed ovarian-talc resolution is another example of aggregation without identical outcomes. J&J has described the agreement in terms of per-claim payments and a total commitment, while publicly available information does not establish one universal payment amount for every claimant. Any website presenting one guaranteed payout for all talc cases should therefore be treated cautiously.
What Is the Average Talcum Powder Lawsuit Settlement?
There is no reliable single average settlement amount that prospective claimants should use to value their case in September 2026. Individual jury verdicts from earlier litigation have sometimes been very large, while other plaintiffs have lost, had awards reduced, settled confidentially, or received different results. Verdicts also differ fundamentally from negotiated settlements and should not be treated as guaranteed payout examples.
The current $5.5 billion figure does not solve that problem. It is a collective J&J commitment tied to roughly 76,000 ovarian claims and participation conditions, while individual allocations depend on the settlement framework rather than simple division. Publicly available sources in September 2026 do not provide a universal amount that every participating claimant will receive.
Mesothelioma should also not be mixed into an ovarian-cancer “average.” J&J’s July announcement said the company had already settled about 95% of filed mesothelioma lawsuits and described those claims separately from the new ovarian-talc agreement. Because the injury, evidence, litigation track, and settlements differ, combining both categories into one advertised average can be misleading.
How Long Do You Have to File?
There is no single nationwide talcum-powder statute of limitations. A statute of limitations establishes how long a person has to bring a claim, and Cornell’s Legal Information Institute notes that the period varies by jurisdiction and type of claim. Depending on the applicable law, the clock may relate to the date of injury, the date an injury was discovered, or when it reasonably should have been discovered.
Cancer cases can make this issue especially important because diagnosis may occur years after the alleged exposure. Some states apply discovery-related rules, while statutes of repose or other doctrines can create additional complications. Wrongful-death claims can also have a different accrual date or limitations period from an original personal-injury claim.
For that reason, a reader should not rely on a website saying everyone has “two years” or “three years” without specifying the controlling state and cause of action. A lawyer evaluating the actual dates can determine which rule may apply and whether tolling or another exception is relevant. Waiting for the broader settlement to become clearer does not necessarily pause an individual filing deadline.
What Should Current Claimants Do Next?
A claimant already represented in the ovarian-talc litigation should watch communications from their own law firm closely. The settlement administrator states that people identified as eligible may receive individualized Opt-In & Release paperwork and that the return deadline is generally 30 days from when that document is sent. Because the paperwork concerns a claimant’s legal rights, questions about signing, eligibility, payment classification, or timing should go to the firm representing that person.
Someone who has been diagnosed with ovarian cancer or mesothelioma after substantial talc exposure but has never filed a claim faces a different decision. That person should first establish the relevant diagnosis and exposure history, then have an attorney determine whether a timely claim remains available under the applicable state’s law. The existence of a settlement program for existing ovarian claims should not be treated as proof that every new claimant can enter it.
People should also be cautious about unsolicited contacts claiming to guarantee settlement money. The official TCRP site specifically warns about potential impersonation and states that the settlement administrator will not contact a claimant unless the claimant has requested assistance through the program’s process. Verifying communications through the law firm already handling the case or the official program can reduce the risk of handing sensitive information to an impersonator.
Frequently Asked Questions
Is the talcum powder lawsuit still active in 2026?
Yes, substantial litigation remained active as of September 2026. The JPML’s September 1 report listed 69,250 pending actions in federal MDL 2738, even as the parties worked on a proposed resolution of most remaining ovarian-cancer claims. State-court and mesothelioma matters can follow separate procedural tracks.
Did Johnson & Johnson agree to a $5.5 billion settlement?
Johnson & Johnson announced a $5.5 billion commitment on July 27, 2026, to resolve roughly 76,000 ovarian-talc claims under specified conditions. The agreement requires participation representing at least 95% of remaining claims, and J&J continues to deny that its talc products caused cancer. Claimants should therefore describe it as a conditional resolution rather than a guaranteed payment to every person who used talcum powder.
How much will each person receive from the talcum powder settlement?
There is no reliable universal per-person amount published for all claimants. Settlement values can depend on the program’s criteria and the facts assigned to an individual claim, while mesothelioma matters are not the same as the ovarian-cancer resolution. The official claimant website tells participants to contact their own law firms about potential settlement amounts.
Can someone still file a talcum powder lawsuit?
A person may still have a potential claim if the applicable filing deadline has not expired and the facts support a legally recognized injury and exposure theory. The answer depends on factors such as diagnosis, product history, jurisdiction, and the relevant statute of limitations rather than one nationwide cutoff date. Participation in the current ovarian-cancer settlement program is a separate eligibility question from whether someone can initiate a new lawsuit.
Does talcum powder definitely cause ovarian cancer?
Scientific authorities do not state the issue that simply. IARC classifies talc as probably carcinogenic to humans and a 2024 NIH-led study found an association between genital talc use and ovarian cancer, while the National Cancer Institute describes the epidemiologic evidence as inconsistent and inadequate to establish an association. An association at the population level also does not by itself prove that talc caused one particular individual’s cancer.
Are mesothelioma claims included in the new ovarian-cancer settlement?
The July 2026 agreement is primarily a resolution of remaining ovarian-talc claims rather than one global payment program for every talc-related disease. J&J said it had separately resolved about 95% of filed mesothelioma lawsuits, while additional mesothelioma matters have continued to be treated on their own track. Anyone with a mesothelioma diagnosis should therefore avoid assuming that ovarian-settlement rules or estimated payments apply to their case.
Bottom Line
The talcum powder lawsuit landscape changed significantly in 2026, but it has not become simple. Johnson & Johnson’s $5.5 billion ovarian-talc resolution offers a potential path toward resolving tens of thousands of claims, while 69,250 federal actions were still listed as pending on September 1, and settlement participation procedures were underway. The appropriate next step depends on whether someone is an existing claimant, a person considering a new case, or a family dealing with a mesothelioma or wrongful-death claim.
For an existing claimant, communications from the person’s own law firm and the official settlement program should take priority over generic internet estimates. For someone considering a claim, preserving medical and product-use records and determining the applicable state deadline are more useful than trying to calculate an “average payout.” Readers looking for broader legal explainers can also explore Notepare’s Law section.
